Maravai reports Q2 2026 revenue up 8.5%, raises full-year Adjusted EBITDA guidance
Maravai posted $51.4 million in quarterly revenue and narrowed its net loss, while lifting its 2026 Adjusted EBITDA outlook to $33 million to $35 million.
Maravai LifeSciences Holdings reported financial results for the second quarter ended June 30, 2026, on August 6, 2026. Revenue for the second quarter was $51.4 million, an increase of 8.5% compared to the prior year period, driven by increased demand for research use only raw materials used in drug discovery and GMP products used in clinical trials.1
By segment, TriLink revenue increased 11.5% year-over-year, with increased demand for research use only raw materials used in drug discovery and GMP products used in clinical trials1, while Cygnus revenue increased 2.8% year-over-year, driven by increased demand for Host Cell Protein and ELISA kits and strength in China due to distributor ordering timing.1
Net loss and Adjusted EBITDA (non-GAAP) were $(21.6) million and $8.7 million, respectively, for the second quarter of 2026, compared to net loss and Adjusted EBITDA (non-GAAP) of $(69.8) million and $(10.4) million, respectively, for the second quarter of 2025.1
On the operating side, CEO Bernd Brust said the company reached an important milestone with the opening of its GMP enzyme manufacturing facility, completing TriLink's integrated portfolio of IVT raw materials and strengthening its position as a single-source partner supporting customers from early-stage research through commercial manufacturing.1 He also said the company continued to see strong adoption of its ModTail product line, which has grown to more than 125 active customers in just one year since its commercial launch, including many of the world's leading biopharmaceutical companies.1
The company raised guidance: revenue for the full year 2026 is expected to be in the range of $205.0 million to $215.0 million, and Adjusted EBITDA is now expected to be in the range of $33.0 million to $35.0 million, up from the prior range of $30.0 million to $32.0 million.1 Maravai noted this guidance is based on expectations for its existing business and does not include the financial impact of potential new acquisitions, if any, or items that have not yet been identified or quantified.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.